Anlon Healthcare Analyst Review 2027: Revenue Doubles and H1 Beats All of FY26
- November 19, 2026
- Posted by: Kunal Singla
- Category: Market
Anlon Healthcare Stock Snapshot (18 Nov 2026 close)
- Current Market Price (CMP): ₹25.45
- 52-Week High / Low: ₹37.24 / ₹10.37
- Market Capitalisation: ₹1,352 crore
- P/E Ratio vs Industry P/E: 32.6 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹105.61 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹17.18 crore
Quick Answer: The Anlon Healthcare analyst review 2027 finds no verified brokerage target as of November 2026. Q2 FY27 consolidated revenue rose about 102% to ₹105.61 crore and profit rose about 84% to ₹17.18 crore, with EBITDA margin recovering to 23.9% from 17.8% in Q1. H1 revenue of ₹193.17 crore is already above FY26’s full-year total, and management reiterated FY27 revenue guidance of ₹380 crore to ₹400 crore. Operating cash flow was negative in FY25 and FY26, so the Anlon Healthcare share price target 2027 depends on growth turning into cash.
The Anlon Healthcare analyst review 2027 covers a chemical maker of pharmaceutical intermediates and active pharmaceutical ingredients that listed in 2025. Readers searching for an Anlon Healthcare share price target 2027 will not find a named brokerage figure, so this review relies on reported results and management guidance.
Anlon Healthcare closed at ₹25.45 on 18 November 2026, about 32% below its 52-week high of ₹37.24 and about 2.5 times its low of ₹10.37. This Anlon Healthcare analyst review 2027 covers the September quarter, the acquisition-led growth and what will shape the Anlon Healthcare stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Anlon Healthcare Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified coverage | Not available | Not available | As of November 2026 |
We could not verify a rating or target from a named brokerage as of November 2026. The company is recently listed and small, and institutions hold about 1% of its shares.
Management’s revenue guidance is the clearest forward marker. FY27 revenue of ₹380 crore to ₹400 crore would be more than double FY26’s ₹172 crore. Any Anlon Healthcare share price target 2027 view needs to test that guidance against the second half, which this Anlon Healthcare analyst review 2027 does below.
Q2 FY27 Results in the Anlon Healthcare Analyst Review 2027
| Quarter | Revenue | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹105.66 crore | ₹25.29 crore | ₹17.18 crore |
| Jun 2026 (Q1 FY27) | ₹87.62 crore | ₹15.65 crore | ₹8.28 crore |
| Mar 2026 (Q4 FY26) | ₹50.90 crore | ₹15.30 crore | ₹11.07 crore |
| Dec 2025 (Q3 FY26) | ₹35.78 crore | ₹12.47 crore | ₹5.15 crore |
| Sep 2025 (Q2 FY26) | ₹52.23 crore | ₹13.73 crore | ₹9.32 crore |
Consolidated revenue rose about 102% to ₹105.61 crore from ₹52.2 crore. EBITDA margin recovered to 23.9% from 17.8% in Q1 after price revisions with customers, though it stayed below 26.3% a year earlier. Net profit rose about 84% to ₹17.18 crore.
Standalone revenue grew a slower 15.9% to ₹60.5 crore, so much of the jump came from acquired businesses consolidated into the group. For the Anlon Healthcare analyst review 2027, organic and acquired growth need to be read separately.
How Anlon Healthcare Makes Money
Anlon sells chemical building blocks and finished drug ingredients to pharmaceutical companies.
- Pharmaceutical intermediates: high-purity compounds used as starting materials for APIs.
- Active pharmaceutical ingredients: finished ingredients sold to formulation makers.
- Acquired capacity: Apiqo Organics, acquired in FY26, adds capacity and backward integration.
- New molecules: several APIs are in validation, with commercial supplies targeted from Q3 FY27 onward.
Revenue rose from about ₹120.5 crore in FY25 to ₹172.2 crore in FY26, and profit from ₹20.5 crore to ₹29.1 crore. Operating cash flow was negative in both years, at about minus ₹22 crore and minus ₹59 crore, as working capital grew. That cash gap is the main caution in the Anlon Healthcare analyst review 2027.
Intermediates and APIs are business-to-business products, so a few large customer orders can shift a quarter. Pricing also moves with raw material costs, which explains why margin fell sharply in Q1 before customer price revisions restored it in Q2. Backward integration through Apiqo should, over time, give Anlon more control over input costs, but the benefit only began to flow from Q2 FY27, according to management.
Growth Triggers in the Anlon Healthcare Analyst Review 2027
- Guidance: FY27 revenue of ₹380 crore to ₹400 crore, more than double FY26.
- Margin floor: management guides to an EBITDA margin of at least 24% to 25%, with an aim of 25% to 30%.
- New APIs: molecules moving from validation to commercial supply in late FY27.
- Anlon Medicos: revenue from this unit expected from Q4 FY27.
- Moderate debt: debt to equity of about 0.28 supports the Anlon Healthcare share price target 2027 case.
Key Risks in the Anlon Healthcare Analyst Review 2027
- Negative cash flow: operating cash flow was negative in FY25 and FY26.
- High inventory: inventory rose with the Apiqo consolidation and raw material inflation.
- Regulatory delays: Anlon Medicos revenue was pushed out because of approvals.
- Margin volatility: EBITDA margin swung from 26.3% to 17.8% and back to 23.9% within a year.
- Institutional exit: DII holding fell to 0.06% from 2.83%, a caution in the Anlon Healthcare analyst review 2027.
Compare Anlon Healthcare With Other Pharma Stocks on the Univest Screener
Anlon Healthcare Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (18 Nov 2026 close) | ₹25.45 |
| 52-Week High / Low | ₹37.24 / ₹10.37 |
| Market Capitalisation | ₹1,352 crore |
| P/E (TTM) vs Industry | 32.6 vs 40.1 |
| Price to Book | 5.25 |
| Book Value per Share | ₹4.84 |
| Return on Equity | 13.86% |
| Debt to Equity | 0.28 |
| EPS (TTM) | ₹0.78 |
| FY26 Revenue / Net Profit | ₹172 crore / ₹29 crore |
A P/E of about 32.6 is below the pharma industry figure of about 40, while price to book value is about 5.3. In the Anlon Healthcare analyst review 2027, the multiple looks reasonable only if guidance is met.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 52.68% | 52.68% | No change |
| Foreign Investors (FII) | 0.00% | 1.00% | Up 1.00 pt |
| Domestic Institutions (DII) | 2.83% | 0.06% | Down 2.77 pts |
| Public | 44.49% | 46.26% | Up 1.77 pts |
The promoter group holds 52.68%, led by Punitkumar Rasadia at 34.98% and Meet Vachhani at 17.7%. Domestic funds that held shares after listing have almost fully exited, while a small foreign stake appeared. Thin institutional ownership is part of the Anlon Healthcare analyst review 2027.
What to Watch After the Anlon Healthcare Analyst Review 2027
- Guidance delivery: H2 revenue needs about ₹187 crore to ₹207 crore to meet FY27 guidance.
- Cash flow: a turn to positive operating cash flow.
- Inventory: the planned 20% to 25% liquidation of excess stock.
- New products: commercial supply from APIs in validation.
- Research coverage: a first named note would give an Anlon Healthcare share price target 2027 reference.
Final Word on the Anlon Healthcare Analyst Review 2027
The Anlon Healthcare analyst review 2027 shows a young listed API company that doubled revenue in Q2 and already beat its FY26 revenue in six months. Much of the growth came from acquisitions, cash flow has been negative and institutions have exited.
The Anlon Healthcare stock outlook 2027 depends on meeting FY27 guidance, cash conversion and new product launches. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Anlon Healthcare analyst review 2027 show?
It shows rapid growth led partly by acquisitions. Q2 FY27 revenue rose about 102% to ₹105.61 crore. Profit rose about 84% to ₹17.18 crore. H1 revenue of ₹193.17 crore is already above FY26’s total.
Is there an Anlon Healthcare share price target 2027 from brokerages?
We could not verify a named brokerage target as of November 2026. The stock closed at ₹25.45 on 18 November 2026. It trades about 32% below its 52-week high of ₹37.24.
What is Anlon Healthcare’s FY27 guidance?
Management guides FY27 revenue of ₹380 crore to ₹400 crore. That needs about ₹187 crore to ₹207 crore in H2. EBITDA margin is guided at a floor of about 24% to 25%.
How does Anlon Healthcare make money?
It sells pharmaceutical intermediates and active pharmaceutical ingredients to drug makers. It acquired Apiqo Organics in FY26 for capacity. FY26 revenue was about ₹172 crore.
Is Anlon Healthcare stock expensive based on the Anlon Healthcare analyst review 2027?
The P/E of about 32.6 is below the industry figure of about 40. Price to book is about 5.3. Return on equity is about 13.9%.
What risks does the Anlon Healthcare analyst review 2027 highlight?
The main risks are negative cash flow, high inventory and regulatory delays. Operating cash flow was about minus ₹59 crore in FY26. Domestic institutions cut their stake to 0.06% from 2.83%.
What should investors track after the Anlon Healthcare analyst review 2027?
Track whether H2 revenue reaches ₹187 crore to ₹207 crore. Watch for positive operating cash flow and lower inventory. Commercial supply from new APIs is another key test.